Videos
Evaluating ctDNA-Guided Therapy in Early-Stage Breast Cancer
03/19/2026
At Great Debates Solid Tumors in Miami, Florida, Adam Brufsky, MD, PhD, from UPMC Magee Women’s Hospital, Pittsburgh, Pennsylvania, discusses the role of circulating tumor DNA (ctDNA) and minimal residual disease (MRD) in early-stage breast cancer.
Dr Brufsky highlights that while ctDNA is a promising tool for MRD detection in breast cancer, limitations in assay sensitivity and lack of definitive prospective data mean it should not yet be used to guide adjuvant therapy outside of clinical trials.
Source:
Brufsky A. Should we order ctDNA in the adjuvant setting for early-stage breast cancer outside of clinical trials: Yes vs no. Presented at Great Debates - Solid Tumors; Miami, Florida. March 14-15, 2026.
